IBDEI1RY ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,30160,1,4,0)
 ;;=4^C81.00
 ;;^UTILITY(U,$J,358.3,30160,2)
 ;;=^5001391
 ;;^UTILITY(U,$J,358.3,30161,0)
 ;;=C83.39^^118^1502^22
 ;;^UTILITY(U,$J,358.3,30161,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30161,1,3,0)
 ;;=3^Diffuse large B-cell lymphoma, extrnod and solid organ sites
 ;;^UTILITY(U,$J,358.3,30161,1,4,0)
 ;;=4^C83.39
 ;;^UTILITY(U,$J,358.3,30161,2)
 ;;=^5001580
 ;;^UTILITY(U,$J,358.3,30162,0)
 ;;=C81.09^^118^1502^62
 ;;^UTILITY(U,$J,358.3,30162,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30162,1,3,0)
 ;;=3^Nodular lymphocyte predominant Hodgkin lymphoma, extrnod & solid org site
 ;;^UTILITY(U,$J,358.3,30162,1,4,0)
 ;;=4^C81.09
 ;;^UTILITY(U,$J,358.3,30162,2)
 ;;=^5001400
 ;;^UTILITY(U,$J,358.3,30163,0)
 ;;=C81.10^^118^1502^63
 ;;^UTILITY(U,$J,358.3,30163,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30163,1,3,0)
 ;;=3^Nodular sclerosis classical Hodgkin lymphoma, unsp site
 ;;^UTILITY(U,$J,358.3,30163,1,4,0)
 ;;=4^C81.10
 ;;^UTILITY(U,$J,358.3,30163,2)
 ;;=^5001401
 ;;^UTILITY(U,$J,358.3,30164,0)
 ;;=C81.19^^118^1502^64
 ;;^UTILITY(U,$J,358.3,30164,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30164,1,3,0)
 ;;=3^Nodular sclerosis classical Hodgkin lymphoma,extrnod and solid organ sites
 ;;^UTILITY(U,$J,358.3,30164,1,4,0)
 ;;=4^C81.19
 ;;^UTILITY(U,$J,358.3,30164,2)
 ;;=^5001410
 ;;^UTILITY(U,$J,358.3,30165,0)
 ;;=C81.20^^118^1502^54
 ;;^UTILITY(U,$J,358.3,30165,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30165,1,3,0)
 ;;=3^Mixed cellularity classical Hodgkin lymphoma, unsp site
 ;;^UTILITY(U,$J,358.3,30165,1,4,0)
 ;;=4^C81.20
 ;;^UTILITY(U,$J,358.3,30165,2)
 ;;=^5001411
 ;;^UTILITY(U,$J,358.3,30166,0)
 ;;=C81.29^^118^1502^53
 ;;^UTILITY(U,$J,358.3,30166,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30166,1,3,0)
 ;;=3^Mix cellular class Hdgkn lymph, extrnod and solid org sites
 ;;^UTILITY(U,$J,358.3,30166,1,4,0)
 ;;=4^C81.29
 ;;^UTILITY(U,$J,358.3,30166,2)
 ;;=^5001420
 ;;^UTILITY(U,$J,358.3,30167,0)
 ;;=C81.30^^118^1502^48
 ;;^UTILITY(U,$J,358.3,30167,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30167,1,3,0)
 ;;=3^Lymphocyte depleted classical Hodgkin lymphoma, unsp site
 ;;^UTILITY(U,$J,358.3,30167,1,4,0)
 ;;=4^C81.30
 ;;^UTILITY(U,$J,358.3,30167,2)
 ;;=^5001421
 ;;^UTILITY(U,$J,358.3,30168,0)
 ;;=C81.39^^118^1502^47
 ;;^UTILITY(U,$J,358.3,30168,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30168,1,3,0)
 ;;=3^Lymphocy deplet class Hdgkn lymph, extrnod & solid org site
 ;;^UTILITY(U,$J,358.3,30168,1,4,0)
 ;;=4^C81.39
 ;;^UTILITY(U,$J,358.3,30168,2)
 ;;=^5001430
 ;;^UTILITY(U,$J,358.3,30169,0)
 ;;=C81.40^^118^1502^49
 ;;^UTILITY(U,$J,358.3,30169,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30169,1,3,0)
 ;;=3^Lymphocyte-rich classical Hodgkin lymphoma, unspecified site
 ;;^UTILITY(U,$J,358.3,30169,1,4,0)
 ;;=4^C81.40
 ;;^UTILITY(U,$J,358.3,30169,2)
 ;;=^5001431
 ;;^UTILITY(U,$J,358.3,30170,0)
 ;;=C81.49^^118^1502^44
 ;;^UTILITY(U,$J,358.3,30170,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30170,1,3,0)
 ;;=3^Lymp-rich class Hodgkin lymph, extrnod and solid organ sites
 ;;^UTILITY(U,$J,358.3,30170,1,4,0)
 ;;=4^C81.49
 ;;^UTILITY(U,$J,358.3,30170,2)
 ;;=^5001440
 ;;^UTILITY(U,$J,358.3,30171,0)
 ;;=C81.99^^118^1502^42
 ;;^UTILITY(U,$J,358.3,30171,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30171,1,3,0)
 ;;=3^Hodgkin lymphoma, unsp, extranodal and solid organ sites
 ;;^UTILITY(U,$J,358.3,30171,1,4,0)
 ;;=4^C81.99
 ;;^UTILITY(U,$J,358.3,30171,2)
 ;;=^5001460
 ;;^UTILITY(U,$J,358.3,30172,0)
 ;;=C81.90^^118^1502^43
 ;;^UTILITY(U,$J,358.3,30172,1,0)
 ;;=^358.31IA^4^2
